AbbVie gains option to Teneobio BCMA program

AbbVie Inc. (NYSE:ABBV) will pay $90 million up front for an option to acquire bispecific antibody TNB-383B from Teneobio Inc.

Read the full 209 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE